Picture of OssDsign AB logo

OSSD OssDsign AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Sweden's OssDsign Q1 net sales fall 17%, net loss narrows

Overview

Sweden orthobiologics developer's Q1 net sales fell 17% yr/yr on reported basis

Gross margin declined to 91.6% from 96.4%, mainly due to temporary mix effects

Company reported Q1 net loss narrowed to SEK 11.5 mln from SEK 14.6 mln

Outlook

Company did not provide specific guidance or outlook for future quarters or full year

Result Drivers

CURRENCY IMPACT - Co said the 17% yr/yr decline in reported net sales was mainly due to USD depreciation against SEK

PRODUCT MIX - Gross margin decline to 91.6% from 96.4% was primarily due to temporary mix effects

LOWER VARIABLE COSTS - Operating expenses fell, mainly due to lower sales variable costs such as commissions and fees

Company press release: ID:nWkrKjYPV

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 SalesMissSEK 36.88 mlnSEK 46 mln (1 Analyst)
Q1 EPS-SEK 0.10
Q1 Net Income-SEK 11.47 mln
Q1 Gross Margin91.60%
Q1 Adjusted Free Cash Flow-SEK 14.87 mln
Q1 Operating Profit-SEK 13.47 mln
Analyst Coverage Wall Street's median 12-month price target for OssDsign AB is SEK12.00, about 200.8% above its May 4 closing price of SEK3.99 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on OssDsign AB

See all news